Ondine Biomedical Secures First NHS Commercial Deal with Antimicrobial Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc., a Canadian company specializing in antimicrobial photodisinfection, has secured its first commercial deal with an NHS trust in the United Kingdom. The company's Steriwave technology has been adopted by Pontefract and Pinderfields hospitals following a successful 500-patient elective hip and knee surgical quality initiative at Pontefract. This commercial agreement represents a significant validation of the technology's effectiveness in clinical settings and demonstrates growing acceptance within the UK healthcare system.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed excitement about this milestone achievement. The commercial adoption comes after the company demonstrated positive patient outcomes and favorable health economics during the quality initiative. Ondine now aims to develop a comprehensive business case with the York health economics group and Mid Yorkshire to support broader NHS adoption across the United Kingdom. This strategic approach leverages the successful results from the initial implementation to build a compelling case for wider healthcare system integration.
The UK adoption forms part of Ondine's expanding commercial momentum globally. The Steriwave technology is now deployed in eight new healthcare facilities, bringing the total to 22 facilities across Canada while simultaneously expanding its presence in both the UK and Spain. This international growth reflects increasing recognition of the technology's value in healthcare settings. The success is partly attributed to Steriwave's demonstrated effectiveness in reducing antibiotic usage, as shown in a UK study, and its strong alignment with global antimicrobial resistance mitigation efforts.
Looking ahead, Ondine plans to continue its European market expansion while capitalizing on established success in the Canadian healthcare system. The company is also exploring potential market entry in the United States through ongoing FDA phase three clinical trials. Ondine's innovative approach to antimicrobial photodisinfection positions the technology as a promising solution in the global fight against antibiotic resistance and healthcare-associated infections, addressing critical challenges in modern medical practice.
Curated from News Direct
